995 documents

Read All
03:03 , Feb 15, 2019 |  BC Innovations  |  Tools & Techniques

Heartening predictors in diabetes

New biomarkers of cardiovascular risk could relieve a decade-old bottleneck for diabetes drug development, but validating them will require companies to invest in strategic trial designs, and public and private stakeholders to pool thinking. As...
Read More
19:31 , Feb 7, 2019 |  BC Extra  |  Tools & Techniques

Virtual compound library for high throughput computational drug discovery

University of California San Francisco researchers have launched an updated, publicly available and growing virtual library of over 350 million small molecules, all of which can be synthesized on demand. Combined with high throughput computational...
Read More
17:55 , Jan 11, 2019 |  BC Week In Review  |  Company News

Ex-Juno execs launch cell therapy start-up Sana

Former Juno Therapeutics Inc. executives Steve Harr and Hans Bishop launched Sana Biotechnology Inc. (Seattle, Wash.) on Jan. 4 with the goal of aggregating R&D and manufacturing capabilities across the cell and gene therapy treatment...
Read More
00:29 , Jan 5, 2019 |  BC Extra  |  Company News

Ex-Juno execs launch cell therapy start-up Sana

Former Juno Therapeutics Inc. executives Steve Harr and Hans Bishop launched Sana Biotechnology Inc. (Seattle, Wash.) on Friday with the goal of aggregating R&D and manufacturing capabilities across the cell and gene therapy treatment paradigms....
Read More
20:56 , Dec 14, 2018 |  BioCentury  |  Finance

Mission: Mainstream

Mission Bio Inc. plans to deploy its $30 million series B round to expand the applications and client base for its single-cell DNA analysis platform. Agilent Technologies Inc. (NYSE:A), Cota Capital, Laboratory Corp. of America...
Read More
19:09 , Dec 14, 2018 |  BC Week In Review  |  Financial News

Mission Bio raises $30M series B to expand Tapestri’s reach

Precision genomics company Mission Bio Inc. (South San Francisco, Calif.) raised $30 million on Dec. 13 in an untranched series B round from Agilent Technologies (NYSE:A), Cota Capital, Laboratory Corp. of America Holdings (NYSE:LH), LAM...
Read More
17:00 , Dec 13, 2018 |  BC Extra  |  Financial News

Mission Bio raises $30M series B to expand Tapestri’s reach

Precision genomics company Mission Bio Inc. (South San Francisco, Calif.) raised $30 million in an untranched series B round from Agilent Technologies (NYSE:A), Cota Capital, Laboratory Corp. of America Holdings (NYSE:LH), LAM Research Capital and...
Read More
17:55 , Dec 7, 2018 |  BC Week In Review  |  Clinical News

Legend reports 15 months PFS for anti-BCMA CAR; questions over trial sites linger

Data presented on the most advanced Chinese CAR product at the American Society of Hematology (ASH) meeting don't shed much light on outstanding questions related to the company's data reports from the trial, but do...
Read More
17:46 , Dec 7, 2018 |  BC Week In Review  |  Clinical News

ASH presentations hint at future of BCMA CARs

Enhanced persistence and redirection of universal cells are among approaches companies are using to create the next generation of BCMA (tumor necrosis factor receptor superfamily member 17; TNFRSF17; CD269)-targeted CAR T cell therapies for multiple...
Read More
01:20 , Dec 7, 2018 |  BC Week In Review  |  Company News

NCATS looks to space to mimic aging, launches first experiment

A SpaceX flight scheduled for launch Dec. 5 is due to carry tissue-on-a-chip technology as part of the Tissue Chips In Space initiative, intended to harness microgravity to mimic and accelerate the human body's aging...
Read More